Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.50 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | hard to drug | 0.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 2 Parkinson's papers of 1,468 | 0.85 |
| pathways Reactome | 5 pathways; mostly iron and oxidative stress | 0.80 |
No case: the score is under the bar. Receipt 0239
Sealed predictions
- CDKN2B in dopamine neurons, braak-0.82 (p 0.007) → +0.04 (p 0.925)receipt 0247
Swarm cases
receipt 0247: CDKN2B in dopamine neurons, braak
- power
- full sample -0.25 (p 0.310, n 18), 95% CI -0.64 to +0.24. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.19 (p 0.450, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.38 (p 0.123, n 18). could be the mix.
- skeptic
- leave-one-out range -0.36 to -0.15, sign flips 0; without severely affected donors -0.25 (p 0.310, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for CDKN2B in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts